Translational Approach to KRAS Inhibitors and Mapping the Possible Mechanism of KRASi Resistance

1:30 pm - Wednesday 9th September 2026

  • The KRAS inhibitor Landscape: From Discovery to Clinical Hurdles
  • Establishment of Sotorasib, Adagrasib and Daraxonrasib resistance PDX models. Leveraging MiniPDX and PDX Models for next generation KRASi screening
  • Decoding resistance mechanism through integrated bioinformatics

Speakers:

Vice President of Strategy, Head of Scientific Engagement
LIDE Biotech